Sangamo Therapeutics Inc logo

Sangamo Therapeutics Inc Investor Relations Material

Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in therapeutic genome editing. The company's lead program is focused on treating inherited blood disorder beta-thalassemia and sickle cell disease by ex vivo genome editing in hematopoietic stem and progenitor cells from adult patients. It is also focusing on genome editing for HIV/AIDS; hemophilia; Huntington's disease; LCA6; other rare and infectious diseases; cancer and degenerative conditions. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California

Latest company events

Q1 20222022-05-05
Q4 20212022-02-24
Q3 20212021-11-04
Q2 20212021-08-05
Q1 20212021-05-03

Ticker symbol

SGMO

Country

United States of America

About the company

https://www.sangamo.com/

Investor Relations Page

https://investor.sangamo.com/

Dig deeper into the Sangamo Therapeutics Inc fundamentals on Quartr.

  • Skip straight to the Q&A session
  • Receive notifications about new events
  • Connect the financial calender on your phone
  • Figure out why the stock is up or down
  • Read the transcripts or scroll the deck
  • Access earnings or press releases
App store link
Android play link
Quartr app screenshot